Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Histamine Antagonists × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Urinary Bladder Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Ependymoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma in Situ 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Carboplatin 695 Pemetrexed 535 Cisplatin 484 Paclitaxel 431 pembrolizumab 409 Docetaxel 391 Gemcitabine 286 Erlotinib Hydrochloride 282 Radiotherapy 226 Bevacizumab 213 Nivolumab 212 osimertinib 152 durvalumab 143 Drug Therapy 140 Gefitinib 120 atezolizumab 117 Radiosurgery 112 Vinorelbine 98 Cetuximab 84 130-nm albumin-bound paclitaxel 83 Magnetic Resonance Spectroscopy 80 Taxes 71 Ipilimumab 70 Surgical Procedures, Operative 66 Albumin-Bound Paclitaxel 61 Afatinib 58 Specimen Handling 57 Cyclophosphamide 56 tislelizumab 54 Etoposide 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06305754 2026-03-13

MK-2870-009

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡